Aukera Therapeutics raises funding

A University of Basel spin-off, Aukera Therapeutics develops selective mTORC1 (RAPTOR) inhibitors, initially for tuberous sclerosis complex. Former Numab CEO David Urech has invested an undisclosed amount; the company has raised CHF 4.5 million in total, notably from Kickfund and Zürcher Kantonalbank.

Announced on
Round
Undisclosed round
Amount
Amount not disclosed
Location
canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

  • David Urech

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic